• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    9/14/23 1:31:11 PM ET
    $BEAT
    $BIOL
    $BNOX
    $ELOX
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email

    Gainers

    • First Wave BioPharma (NASDAQ:FWBI) shares moved upwards by 23.8% to $0.54 during Thursday's regular session. As of 13:30 EST, this security is trading at a volume of 121.0 million shares, making up 4158.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.8 million.
    • Synlogic (NASDAQ:SYBX) stock moved upwards by 23.67% to $0.3. The current volume of 316.6K shares is 163.6% of Synlogic's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $20.9 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) stock moved upwards by 22.79% to $1.25. Trading volume for ENDRA Life Sciences's stock is 2.0 million as of 13:30 EST. This is 3431.1% of its average full-day volume over the last 100 days. The company's market cap stands at $9.3 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) stock moved upwards by 19.52% to $1.47. As of 13:30 EST, NeuBase Therapeutics's stock is trading at a volume of 8.1 million, which is 377.5% of its average full-day volume over the last 100 days. The company's market cap stands at $4.5 million.
    • Eloxx Pharmaceuticals (NASDAQ:ELOX) shares rose 18.53% to $5.5. The current volume of 69.1K shares is 7.1% of Eloxx Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $15.1 million.
    • HeartBeam (NASDAQ:BEAT) shares moved upwards by 17.52% to $2.28. HeartBeam's stock is trading at a volume of 289.2K shares as of 13:30 EST. This is 275.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $59.9 million.

    Losers

    • Biolase (NASDAQ:BIOL) shares fell 38.5% to $2.0 during Thursday's regular session. Trading volume for Biolase's stock is 1.2 million as of 13:30 EST. This is 562.9% of its average full-day volume over the last 100 days. The company's market cap stands at $2.0 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares fell 22.23% to $0.7. Trading volume for TransCode Therapeutics's stock is 5.9 million as of 13:30 EST. This is 3983.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.4 million.
    • Bionomics (NASDAQ:BNOX) shares fell 21.79% to $1.4. Trading volume for this security as of 13:30 EST is 516.0K, which is 231.2% of its average full-day volume over the last 100 days. The company's market cap stands at $11.4 million.
    • ZyVersa Therapeutics (NASDAQ:ZVSA) shares declined by 21.11% to $0.15. Trading volume for this security as of 13:30 EST is 17.8 million, which is 413.6% of its average full-day volume over the last 100 days. The company's market cap stands at $4.6 million.
    • Harpoon Therapeutics (NASDAQ:HARP) stock decreased by 20.18% to $5.22. Trading volume for this security as of 13:30 EST is 188.0K, which is 635.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.0 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock decreased by 19.26% to $0.36. As of 13:30 EST, this security is trading at a volume of 51.9 million shares, making up 126.3% of its average full-day volume over the last 100 days. The company's market cap stands at $56.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BEAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAT
    $BIOL
    $BNOX
    $ELOX

    CompanyDatePrice TargetRatingAnalyst
    Heartbeam Inc.
    $BEAT
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    Heartbeam Inc.
    $BEAT
    12/8/2025$2.50Buy
    H.C. Wainwright
    Heartbeam Inc.
    $BEAT
    10/31/2025$4.00Buy
    Roth Capital
    Harpoon Therapeutics Inc.
    $HARP
    1/5/2024$23.00Outperform
    Oppenheimer
    Harpoon Therapeutics Inc.
    $HARP
    11/20/2023Outperform
    TD Cowen
    Bionomics Limited
    $BNOX
    9/28/2023$7.00 → $10.00Buy
    Maxim Group
    Bionomics Limited
    $BNOX
    9/28/2023$8.00Neutral → Buy
    H.C. Wainwright
    Harpoon Therapeutics Inc.
    $HARP
    7/6/2022$16.00Buy
    Canaccord Genuity
    More analyst ratings

    $BEAT
    $BIOL
    $BNOX
    $ELOX
    SEC Filings

    View All

    ZyVersa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

    3/5/26 4:05:37 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by TransCode Therapeutics Inc.

    DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:06:34 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:05:39 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEAT
    $BIOL
    $BNOX
    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartBeam Announces First Patient Enrollments in Heart Attack Detection Pilot Study

    HeartBeam's technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings ALIGN-ACS study expected to complete patient enrollment quickly Milestone signifies key step toward future FDA indication expansion for heart attack assessment Future indication expansion would unlock large market with over 20 million patients at risk of a heart attack HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the first patients have been enrolled in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first pati

    3/5/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will

    3/4/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market

    Marks HeartBeam's transition to commercial company Rapidly growing practice and highly engaged member population to enable broad adoption Enables efficient scaling of additional preventive cardiology and executive health programs Establishes initial foothold in structured direct pay healthcare segment representing 5 million patients HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with ClearCardio™, a leading preventive cardiology practice that has served thousands of patients through advanced heart health screening and personalized prevention programs. In

    3/4/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    $BIOL
    $BNOX
    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HeartBeam upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded HeartBeam from Speculative Buy to Buy and set a new price target of $8.00

    12/11/25 8:45:10 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on HeartBeam with a new price target

    H.C. Wainwright initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.50

    12/8/25 8:34:44 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Roth Capital initiated coverage on HeartBeam with a new price target

    Roth Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

    10/31/25 8:19:51 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    $BIOL
    $BNOX
    $ELOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 8:00:22 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 7:55:14 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

    4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    9/5/24 3:28:10 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BEAT
    $BIOL
    $BNOX
    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:18 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Digiandomenico Anthony was granted 60,324 shares, increasing direct ownership by 79% to 136,589 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    1/23/26 7:44:04 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $BEAT
    $BIOL
    $BNOX
    $ELOX
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEAT
    $BIOL
    $BNOX
    $ELOX
    Financials

    Live finance-specific insights

    View All

    HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will

    3/4/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

    ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases.The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS) with potential indication expansion in Alport syndrome and diabetic kidney disease.The lead indication for IC 100 is cardiometabolic conditions, with potential indication expansion in rare kidney diseases.Raised approximately $2.05 million in Q3-2025; $4.05 million year-to-date. WESTON, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- ZyVersa Th

    11/19/25 4:20:00 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartBeam Reports Third Quarter 2025 Results

    Commercial Readiness Plans Accelerating in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software for Arrhythmia Assessment Anticipated FDA Clearance in Q4 2025 is a Major Inflection Point as HeartBeam Evolves into a Commercial-Stage Company Focused on Growth Announced Partnership with HeartNexus to Provide On-Demand Cardiologist Reviews of Synthesized 12-Lead ECGs for Arrhythmia Assessment and Triage Patients Data Presented at AHA Scientific Sessions and HRX Live 2025 Continue to Advance HeartBeam's Pipeline for Ischemia Detection and Deep Learning Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. E

    11/13/25 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    $BIOL
    $BNOX
    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

    SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    11/14/24 6:01:27 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

    SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

    11/14/24 4:40:57 PM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Bionomics Limited

    SC 13G - BIONOMICS LIMITED/FI (0001191070) (Subject)

    11/14/24 3:25:19 PM ET
    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care